Search Results 921-930 of 14777 for anti-TNF drugs

1. Antihemophilic Factor (Recombinant), Fc-Vwf-Xten Fusion Protein-Ehtl (Intravenous Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects.

2. Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Subcutaneous Route) Description and Brand Names - Mayo Clinic

   It is also used after an initial treatment plan to treat HER2-positive early breast cancer which has a high risk of occurring again.

3. Selinexor Treatment of Refractory Myeloma - Mayo Clinic

   ... anti-CD38 mAb, daratumumab. Refractory is defined as ≤ 25% response to therapy, or progression during therapy or progression within 60 days after ...

4. Tapentadol (Oral Route) Description and Brand Names - Mayo Clinic

   Tapentadol oral solution and tablet are used to treat pain severe enough to require opioid treatment and when other pain medicines did not work well enough or ...

5. Levonorgestrel And Ethinyl Estradiol (Oral Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Alesse; Alesse-28; Altavera; Amethia ...

6. Mayo Clinic Comprehensive Cancer Center Research

   ... anti-PD-1 antibody blockade enhances anti-tumor activity in glioblastoma treatment; Demonstrating that intraperitoneal administration of measles virus-sodium ...

7. Clindamycin And Tretinoin (Topical Application Route) Precautions - Mayo Clinic

   Some medicines may make your diarrhea worse or make it last longer. This medicine may make your skin more sensitive to sunlight, wind, and cold weather. Use a ...

8. A Study to Evaluate Remicade (Infliximab) for the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection and are at an Increased Risk of Recurrence - Mayo Clinic

   ... treatment with adalimumab and/or certolizumab. Must undergo screening for HBV; Baseline CDAI < 200; Has adequate blood and liver test values. Exclusion Criteria.

9. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma - Mayo Clinic

   Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. Participating Mayo Clinic locations. Study statuses change often. Please contact ...

10. Tetracycline (Class) (Oral Route, Parenteral Route) Precautions - Mayo Clinic

    Precautions. Drug information provided by: Merative, Micromedex®. If your symptoms do not improve within a few days (or a few weeks or ...